Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion on August 05, 2025 Acute onset pain Approved Drug Development Journavx non-opioid pain drugs Pain management Peripheral neuropathic pain Sodium Channel Blockers United States Food and Drug Administration VX-993 +
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic on March 17, 2025 Acute onset pain Biotherapeutics Chronic pain Clinical Trials inhibitors Latigo non-opioid pain drugs SCN10A gene Series B +